Doxorubicin-Loaded Polyelectrolyte Multilayer Capsules Modified with Antitumor DR5-Specific TRAIL Variant
Carriers providing active targeted delivery of anticancer drugs to tumor cells are promising for cancer chemotherapy. A team of scientists from the IBCh RAS in collaboration with collegues from other Russian Institutes have developed biodegradable polyelectrolyte microcapsules which have been modified with the DR5-B ligand. The latter is a promising recombinant analogue of the cytokine TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), which specifically binds to the DR5 death receptor overexpressed on the tumor (but not normal) cell membrane. In addition, the capsules were loaded with the anticancer drug doxorubicin (DOX) in a subtoxic concentration. The capsules were demonstrated to provide a targeted drug delivery to tumor cells, as well as a synergistic anticancer effect. The results are published in Nanomaterials. Learn more
march 29, 2023